Literature DB >> 23171584

Pyoderma gangrenosum, acne and suppurative hidradenitis syndrome following bowel bypass surgery.

Angelo V Marzano1, Rim S Ishak, Antonella Colombo, Francesco Caroli, Carlo Crosti.   

Abstract

The clinical triad of pyoderma gangrenosum (PG), acne and suppurative hidradenitis (PASH) has recently been described as a new disease entity within the spectrum of autoinflammatory syndromes, which are an emerging group of inflammatory diseases distinct from autoimmune, allergic and infectious disorders. PASH syndrome is similar to PAPA (pyogenic arthritis, acne and PG), but it differs in lacking the associated arthritis and on a genetic basis. PAPA syndrome is caused by mutations in a gene involved in the regulation of innate immune responses, the PSTPIP1, while no mutations have been detected to date in patients with PASH syndrome. We report a young male patient who developed coexisting disseminated PG, typical suppurative hidradenitis and acneiform eruption on the face, after he had undergone bowel bypass surgery for obesity. The cutaneous manifestations associated with bowel bypass syndrome often mimic PG or other neutrophilic dermatoses, suggesting a pathogenesis related to neutrophil-mediated inflammation for this condition. This is the first report describing PASH syndrome after bariatric surgery, and we propose to include such neutrophilic dermatoses in the list of complications occurring after bowel bypass surgery. Extensive genetic studies may help to clarify the etiopathogenesis of PASH as well as of autoinflammatory diseases in general.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23171584     DOI: 10.1159/000343602

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  6 in total

1.  Successful use of adalimumab to treat pyoderma gangrenosum, acne and suppurative hidradenitis (PASH syndrome) following colectomy in ulcerative colitis.

Authors:  Bryan Murphy; Graham Morrison; Pat Podmore
Journal:  Int J Colorectal Dis       Date:  2015-01-07       Impact factor: 2.571

2.  [PAPA syndrome with Crohn's disease and primary sclerosing cholangitis/autoimmune hepatitis overlap syndrome].

Authors:  Holger Schäffler; Theresia Blattmann; Annette Findeisen; Felix G Meinel; Almut Meyer-Bahlburg; Georg Lamprecht; Lars Steinmüller-Magin; Ralf Trauzeddel; Steffen Emmert
Journal:  Hautarzt       Date:  2019-02       Impact factor: 0.751

3.  Association of pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) shares genetic and cytokine profiles with other autoinflammatory diseases.

Authors:  Angelo V Marzano; Isabella Ceccherini; Marco Gattorno; Daniele Fanoni; Francesco Caroli; Marta Rusmini; Alice Grossi; Clara De Simone; Orietta M Borghi; Pier Luigi Meroni; Carlo Crosti; Massimo Cugno
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

4.  Associated factors and comorbidities in patients with pyoderma gangrenosum in Germany: a retrospective multicentric analysis in 259 patients.

Authors:  Philipp Al Ghazal; Katharina Herberger; Jörg Schaller; Anke Strölin; Norman-Philipp Hoff; Tobias Goerge; Hannelore Roth; Eberhard Rabe; Sigrid Karrer; Regina Renner; Jan Maschke; Thomas Horn; Julia Hepp; Sabine Eming; Uwe Wollina; Markus Zutt; Isabell Sick; Benno Splieth; Dorothea Dill; Joachim Klode; Joachim Dissemond
Journal:  Orphanet J Rare Dis       Date:  2013-09-08       Impact factor: 4.123

Review 5.  An Integrated Approach to Unravel Hidradenitis Suppurativa Etiopathogenesis.

Authors:  Paola M Tricarico; Michele Boniotto; Giovanni Genovese; Christos C Zouboulis; Angelo V Marzano; Sergio Crovella
Journal:  Front Immunol       Date:  2019-04-25       Impact factor: 7.561

6.  PsAPASH: a rare and recent autoinflammatory syndrome associated with hidradenitis suppurativa.

Authors:  Raissa de Lima Gadelha; Renata da Silveira Rodrigues Paiva; Esther Bastos Palitot; Joanne Elizabeth Ferraz da Costa
Journal:  An Bras Dermatol       Date:  2020-01-21       Impact factor: 1.896

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.